Tech Company Financing Transactions
EpiVax Oncology Funding Round
On 6/14/2018, EpiVax Oncology secured $1.2 million in investment from Accelerate New York Seed Fund, Horatio Ventures NYC and Morningside Group.
Transaction Overview
Company Name
Announced On
6/14/2018
Transaction Type
Venture Equity
Amount
$1,200,000
Round
Undisclosed
Proceeds Purpose
Securing this funding is an important milestone because it ensures our continued advancement, and preparation for our Phase 1b clinical trial in bladder cancer and serves as a bridge to our planned Series A financing. We are laser focused on our lead development program and anticipate an IND submission at the end of 2018.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
188 Valley St. 424
Providence, RI 02909
USA
Providence, RI 02909
USA
Phone
Website
Email Address
Overview
Incorporated in 2017 and based in both Providence, RI and New York City, EpiVax Oncology Inc. is a spin-out of EpiVax Inc. EpiVax Oncology leverages EpiVax's world class excellence in computational-immunology, genomics and vaccine design, built over the last 20 years.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gad Berdugo
Chief Technical Officer
Dominique Bridon
President
Anne De Groot
VP - R & D
Michael Princiotta
Browse more venture capital transactions:
Prev: 6/14/2018: NYIAX venture capital transaction
Next: 6/14/2018: Two Bit Circus venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on tech company VC transactions. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs